UK markets close in 3 hours 58 minutes

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
2.9600+0.0800 (+2.78%)
At close: 04:00PM EDT
2.9900 +0.03 (+1.01%)
Pre-market: 06:07AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.8800
Open2.8500
Bid0.0000 x 1200
Ask2.9900 x 38500
Day's range2.8200 - 2.9850
52-week range2.0900 - 15.8640
Volume25,876,854
Avg. volume21,777,274
Market cap5.259B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.6720
Earnings date16 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.43
  • Simply Wall St.

    Ginkgo Bioworks Holdings (NYSE:DNA) shareholders have endured a 73% loss from investing in the stock a year ago

    The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

  • Business Wire

    Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

    SOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement in

  • Business Wire

    Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics

    BRISBANE, Australia & BOSTON, April 04, 2022--Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases. The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo's high throughput,